The Cancer Survivors Network (CSN) is a peer support community for cancer patients, survivors, caregivers, families, and friends! CSN is a safe place to connect with others who share your interests and experiences.

Thank you for being a part of the Cancer Survivor Network community. Survivors and caregivers like you have played a unique role in fostering an online environment that encourages connection among those needing support, community, and education. On May 28, the Network will be discontinued. More details are available here . If you have any questions, contact CSNSupportTeam@cancer.org. Thanks again for the support you’ve provided each other over the years. We remain committed to supporting you in other ways throughout your cancer journey.

Libtayo

Theasp
Theasp CSN Member Posts: 3
edited July 2019 in Skin Cancer #1

Have just been prescribed a course of Libtayo for metisized squamous cell carcinoma wondered if anyone here had any experience with this medication?

Comments

  • Theasp
    Theasp CSN Member Posts: 3
    Libtayo

    New member, making posting mistakes...

     

  • perriced
    perriced CSN Member Posts: 3
    edited December 2020 #3
    Libtayo (cemiplimab)

    I trust by now you have seen positive results.  The great worry is that only slightly less than 50% of patients are responders.

    i am very fortunate to be a responder, and I am having--knock on wood--some very positive success on Libtayo (cemiplimab) on an 11cm metastasized squamous cell tumor on my psoas muscle.  As of month six scan, it has shrunk "significantly" to around 3 cm.  An additional tumor in my right axillary has essentially disappeared.  My oncologist plans to continue treatment until March 2021 when he will pause treatment, and we'll begin monitoring.

  • perriced
    perriced CSN Member Posts: 3
    edited December 2020 #4
    Libtayo Ipilimumab Keytruda

    PS. If, by chance, you are not too familiar with advances in immunotherapy, this is an excellent place to start, a biography of their inventor, Dr. Jim Allison.

    https://www.breakthroughdoc.com/